EXHIBIT 31.1

                                  CERTIFICATION

I, David Lieberman, certify the following:

      1.    I have reviewed this quarterly report on Form 10-QSB/A of Advanced
            Plant Pharmaceuticals, Inc.;

      2.    Based on my knowledge, this report does not contain any untrue
            statement of a material fact or omit to state a material fact
            necessary to make the statements made, in light of the circumstances
            under which such statements were made, not misleading with respect
            to the period covered by this report;

      3.    Based on my knowledge, the financial statements, and other financial
            information included in this report, fairly present in all material
            respects the financial condition, results of operations and cash
            flows of Advanced Plant Pharmaceuticals, Inc. as of, and for, the
            periods presented in this report;

      4.    I am responsible for establishing and maintaining disclosure
            controls and procedures (as defined in Exchange Act Rules 13a-15(e)
            and 15d-15(e)) and internal control over financial reporting (as
            defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Advanced
            Plant Pharmaceuticals, Inc. and I have done the following:

            a.    designed such disclosure controls and procedures, or caused
                  such disclosure controls and procedures to be designed under
                  my supervision, to ensure that material information relating
                  to Advanced Plant Pharmaceuticals, Inc., including its
                  consolidated subsidiaries, is made known to us by others
                  within those entities, particularly during the period in which
                  this report is being prepared;

            b.    designed such internal control over financial reporting, or
                  caused such internal control over financial reporting to be
                  designed under my supervision, to provide reasonable assurance
                  regarding the reliability of financial reporting and the
                  preparation of financial statements for external purposes in
                  accordance with generally accepted accounting principles;

            c.    evaluated the effectiveness of Advanced Plant Pharmaceuticals,
                  Inc.'s disclosure controls and procedures and presented in
                  this report our conclusions about the effectiveness of the
                  disclosure controls and procedures, as of the end of the
                  period covered by this report based on such evaluation; and

            d.    disclosed in this report any change in Advanced Plant
                  Pharmaceuticals, Inc.'s internal control over financial
                  reporting that occurred during Advanced Plant Pharmaceuticals,
                  Inc.'s most recent fiscal quarter that has materially
                  affected, or is reasonably likely to materially affect,
                  Advanced Plant Pharmaceuticals, Inc.'s internal control over
                  financial reporting; and

      5.    I have disclosed, based on my most recent evaluation of internal
            control over financial reporting, to Advanced Plant Pharmaceuticals,
            Inc.'s auditors and the audit committee of Advanced Plant
            Pharmaceuticals, Inc.'s board of directors:

            a.    All significant deficiencies and material weaknesses in the
                  design or operation of internal control over financial
                  reporting which are reasonably likely to adversely affect
                  Advanced Plant Pharmaceuticals, Inc.'s ability to record,
                  process, summarize and report financial information; and

            b.    Any fraud, whether or not material, that involves management
                  or other employees who have a significant role in Advanced
                  Plant Pharmaceuticals, Inc.'s internal control over financial
                  reporting.


January 9, 2007                         /s/ David Lieberman
                                        ----------------------------------------
                                        David Lieberman
                                        President, Chief Executive Officer and
                                        Chief Financial Officer
                                        (Principal Executive, Financial and
                                        Accounting Officer)